APLS
$61.58
Revenue | $99.18Mn |
Net Profits | $-140.24Mn |
Net Profit Margins | -141.39% |
Apellis Pharmaceuticals Inc’s revenue jumped 349.68% since last year same period to $99.18Mn in the Q3 2023. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated 4.44% jump in its revenue since last 3-months.
Apellis Pharmaceuticals Inc’s net profit jumped 26.68% since last year same period to $-140.24Mn in the Q3 2023. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -14.91% fall in its net profits since last 3-months.
Apellis Pharmaceuticals Inc’s net profit margin jumped 83.7% since last year same period to -141.39% in the Q3 2023. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -10.03% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Current Year | -0.87 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.87 - a -1.16% fall from last quarter’s estimates.
Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.87.
Earning Per Share (EPS) | -1.17 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 33.14% since last year same period to -1.17 in the Q3 2023. This indicates that the Apellis Pharmaceuticals Inc has generated 33.14% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-07-31 | -1.32 | -1.02 | 22.73% |
2023-05-04 | -1.46 | -1.56 | -6.85% |
2023-11-01 | -0.86 | -1.17 | -36.05% |